GLP-1 Side Effects: What Most People Actually Experience

Short answer: nausea and other digestive symptoms affect a large share of people starting GLP-1 medications — roughly 3 to 4 in 10, depending on the drug and dose — and these are usually most intense early on and improve over time. Serious complications are documented but uncommon. Here's what the actual data shows, not just the headline warnings.

Every GLP-1 medication comes with a long list of possible side effects on the label, which can make it hard to tell what's actually likely to happen to you versus what's a rare, worst-case scenario. This breaks down both — the common, expected symptoms and the rare but serious ones — using FDA labeling and real-world adverse event data.

The Common Stuff: Gastrointestinal Symptoms

This is, by a wide margin, the main category of side effect for every GLP-1 and dual-agonist medication currently approved.

Wegovy (Semaglutide)

FDA labeling lists the most common side effects (occurring in 5% or more of patients) as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, belching, low blood sugar (in people with diabetes), gas, and heartburn.^[1] In STEP-1, nausea specifically was reported in 44.2% of people on semaglutide 2.4 mg (vs. 17.4% on placebo) — a substantial share, though most cases were mild to moderate rather than severe and typically transient.^[2][1]

Zepbound (Tirzepatide)

Zepbound's label lists a similar core group: nausea, diarrhea, vomiting, constipation, abdominal pain, injection-site reactions, fatigue, hypersensitivity reactions, hair loss (alopecia), dyspepsia, and GERD-related symptoms.^[3] Gastrointestinal events are the dominant adverse-event category in labeling and in SURMOUNT-1, with nausea again the single most common individual symptom — generally a somewhat lower reported nausea rate than for semaglutide 2.4 mg in STEP-1, though both drugs share the same basic symptom profile.^[3]

Why This Happens

These symptoms aren't random — they're a direct consequence of how the medications work. GLP-1 and dual GIP/GLP-1 agonists deliberately slow down stomach emptying and intestinal movement as part of how they create fullness and reduce appetite. That same slowing is what produces nausea, bloating, and reflux in many people. On top of that, these medications can shift food preferences and cause aversions to foods — particularly high-fat foods — that were previously enjoyed without issue, which can itself trigger nausea if those foods are eaten anyway.

The Timeline: It Usually Gets Better

Across labeling, trial data, and clinical guidance, GI side effects follow a consistent pattern: they show up most intensely early on — especially during dose escalation — and tend to decrease as the body adjusts to a stable dose.^[1][8]This is actually the entire reason the titration schedules for both drugs start low and increase gradually: it's a deliberate design choice to reduce the severity of these exact symptoms, not an arbitrary bureaucratic delay.

What Tends to Help

Based on clinical guidance and prescribing information, a few practical approaches are commonly recommended:^[8][1]

• Following the titration schedule as prescribed rather than rushing to a higher dose
• Eating smaller, more frequent meals rather than large ones
• Avoiding very high-fat meals, particularly around injection days
• Staying well-hydrated
• Taking your weekly injection on the same day each week to keep a predictable rhythm

If GI symptoms become severe, prescribers may hold a dose or reduce it temporarily — this is a normal part of managing treatment, not a sign that something has gone wrong or that you need to stop altogether.

Serious but Uncommon Risks

Beyond the GI symptoms, both medications carry warnings for more serious, though considerably less common, complications.

Thyroid C-Cell Tumors (Boxed Warning)

Both Wegovy and Zepbound carry the FDA's most serious type of warning — a boxed warning — for thyroid C-cell tumors, based on findings in rodent studies where these drugs caused thyroid tumors at high doses.^[1][3] Because of this, both medications are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.^[1][3]It's worth noting that the human relevance of the rodent findings remains genuinely uncertain — long-term human monitoring hasn't shown a clear causal link to thyroid cancer in people, but the warning and the contraindication remain in place out of caution.

Pancreatitis

Both drugs' labels warn about acute pancreatitis, with instructions to seek immediate medical care for severe abdominal pain — especially pain that radiates to the back, with or without vomiting.^[1][3]Some post-marketing reports have linked GLP-1 medications to pancreatitis, though a definitive causal relationship hasn't been established.

Gallbladder Disease

Gallstones and gallbladder inflammation are also called out in both labels.^[1][3] This connection isn't entirely about the drug itself — rapid weight loss of any kind, from any cause, increases gallstone risk, and GLP-1-driven weight loss is no exception. Some trial participants have needed gallbladder removal during treatment.

Who Shouldn't Take These Medications

Beyond the thyroid-related contraindications above, these medications aren't recommended for anyone with severe gastroparesis (a condition that already delays stomach emptying), since the drugs' own effect on gastric emptying could worsen those symptoms.^[1][3]

What the Larger Safety Data Shows

Beyond clinical trials, regulators track real-world side effect reports through a system called FAERS (FDA Adverse Event Reporting System). A few things stand out from recent analyses of that data:

• One pharmacovigilance study identified 287,201 unique adverse event reports associated with GLP-1 receptor agonists (through March 31, 2024), with semaglutide products showing elevated reporting odds for serious events compared to other GLP-1 medications in that analysis.^[4] That is a reporting signal — not proven higher true incidence.
• A separate FAERS analysis focused on GI-related reports found semaglutide associated with higher reporting odds for nausea, vomiting, and delayed gastric emptying versus comparators.^[5]
• Labeling already calls out gallbladder disease, and ongoing post-marketing surveillance continues to watch class safety patterns as use expands — signals in FAERS warrant monitoring, not automatic confirmation of new risks.^[1][3][4]

It's worth keeping this kind of data in perspective: FAERS reports are voluntary and don't prove that a medication caused a given event — they're a monitoring tool, not a diagnosis. But the scale of reporting does reflect how widely these medications are now being used, and regulators continue to track patterns as that usage grows.^[4]

A Note on Dosing Errors

Separately, America's Poison Centers (National Poison Data System) have documented a large rise in calls related to GLP-1 medications in recent years — most often about accidental therapeutic errors (doses too close together, or confusion around compounded product dosing units) rather than intentional misuse.^[6]This underscores something worth taking seriously regardless of which GLP-1 medication you're on: understanding exactly how to measure and administer your specific dose, and asking your provider or pharmacist directly if anything about your prescription's dosing instructions is unclear.

Muscle Loss: A Less-Discussed Side Effect

One aspect of GLP-1 treatment that gets less attention than nausea or pancreatitis is body composition — specifically, that not all the weight lost on these medications is fat.

A 2025 review of body composition data across obesity trials found that lean-mass reductions are heterogeneous: some studies report lean tissue as roughly 15% or less of total weight lost, while others report shares in the 40–60% range — so a meaningful share of total weight lost can be lean tissue, but there is no single tight band that fits every trial.^[7] Most of the weight lost is still typically fat, but the lean tissue loss is real and clinically meaningful, and appears more relevant for older adults and those already at risk of age-related muscle loss.

Obesity and geriatric medicine specialists generally interpret this as a reason to pair GLP-1 treatment with resistance exercise and adequate protein intake — not to offset the medication's effect on appetite, but specifically to help preserve muscle mass and physical function while the medication does its work on fat loss.^[7][8] This is particularly relevant for older adults, where muscle preservation has direct implications for long-term mobility and independence.

Frequently Asked Questions

See also: Muscle Loss on GLP-1 Medications for a deeper look at body composition during treatment and what helps protect lean mass, and How Long Does It Take for GLP-1 Medications to Work? for the full week-by-week progression including when side effects typically peak.